NZ217821A
(en)
*
|
1985-10-10 |
1989-07-27 |
Biotech Australia Pty Ltd |
Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
|
US5672334A
(en)
*
|
1991-01-16 |
1997-09-30 |
Access Pharmaceuticals, Inc. |
Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
|
US5707604A
(en)
*
|
1986-11-18 |
1998-01-13 |
Access Pharmaceuticals, Inc. |
Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
|
US5807832A
(en)
*
|
1987-06-09 |
1998-09-15 |
Biotech Australia Pty Limited |
Oral delivery of biologically active substances bound to vitamin B12
|
US5213788A
(en)
*
|
1988-09-29 |
1993-05-25 |
Ranney David F |
Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
|
WO1990003190A1
(en)
*
|
1988-09-29 |
1990-04-05 |
Ranney David F |
Methods and compositions for magnetic resonance imaging
|
US5260050A
(en)
*
|
1988-09-29 |
1993-11-09 |
Ranney David F |
Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
|
US5997856A
(en)
*
|
1988-10-05 |
1999-12-07 |
Chiron Corporation |
Method and compositions for solubilization and stabilization of polypeptides, especially proteins
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
DE69027941T2
(de)
*
|
1989-11-27 |
1997-01-23 |
Nippon Shinyaku Co Ltd |
Fettemulsion
|
US5227372A
(en)
*
|
1990-03-07 |
1993-07-13 |
Children's Medical Center Corporation |
Method for retaining ophthalmological agents in ocular tissues
|
US6613306B1
(en)
|
1990-04-02 |
2003-09-02 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
USRE39146E1
(en)
|
1990-04-02 |
2006-06-27 |
Bracco International B.V. |
Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
|
US7083778B2
(en)
|
1991-05-03 |
2006-08-01 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
US6989141B2
(en)
|
1990-05-18 |
2006-01-24 |
Bracco International B.V. |
Ultrasound contrast agents and methods of making and using them
|
IN172208B
(de)
*
|
1990-04-02 |
1993-05-01 |
Sint Sa |
|
AU647484B2
(en)
*
|
1990-04-26 |
1994-03-24 |
Cytrx Corporation |
Composition and method for topical treatment of damaged or diseased tissue
|
US5216130A
(en)
*
|
1990-05-17 |
1993-06-01 |
Albany Medical College |
Complex for in-vivo target localization
|
AU707085B2
(en)
*
|
1991-04-02 |
1999-07-01 |
Access Pharmaceuticals Australia Pty Limited |
Oral delivery systems for microparticles
|
IE921050A1
(en)
*
|
1991-04-02 |
1992-10-07 |
Biotech Australia Pty Ltd |
Oral delivery systems for microparticles
|
US5705178A
(en)
*
|
1991-05-31 |
1998-01-06 |
Gliatech, Inc. |
Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
|
US5605938A
(en)
*
|
1991-05-31 |
1997-02-25 |
Gliatech, Inc. |
Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
|
GB9119762D0
(en)
*
|
1991-09-16 |
1991-10-30 |
Filler Aaron G |
Particulate agents for nmt
|
IL104084A
(en)
|
1992-01-24 |
1996-09-12 |
Bracco Int Bv |
Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
|
FR2687071B1
(fr)
*
|
1992-02-10 |
1995-06-23 |
Exsymol Sa |
Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
|
US5474765A
(en)
*
|
1992-03-23 |
1995-12-12 |
Ut Sw Medical Ctr At Dallas |
Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
|
AU4693093A
(en)
*
|
1992-07-27 |
1994-02-14 |
Haemacure Biotech Inc. |
Biocompatible surgical implant
|
JP3337075B2
(ja)
*
|
1992-08-05 |
2002-10-21 |
名糖産業株式会社 |
小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
|
PT619730E
(pt)
*
|
1992-10-08 |
2001-04-30 |
Supratek Pharma Inc |
Composicao de agentes anti-neoplasticos incorporados em micelas
|
US5362425A
(en)
*
|
1992-10-22 |
1994-11-08 |
Technology Unlimited, Inc. |
Organic oil spray-drying techniques
|
US5439686A
(en)
*
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
US5916596A
(en)
*
|
1993-02-22 |
1999-06-29 |
Vivorx Pharmaceuticals, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
EP0684814B1
(de)
*
|
1993-02-22 |
1998-06-17 |
Alza Corporation |
Mittel zur oralen gabe von wirkstoffen
|
US6528067B1
(en)
|
1993-02-22 |
2003-03-04 |
American Bioscience, Inc. |
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
US5665382A
(en)
*
|
1993-02-22 |
1997-09-09 |
Vivorx Pharmaceuticals, Inc. |
Methods for the preparation of pharmaceutically active agents for in vivo delivery
|
US5650156A
(en)
*
|
1993-02-22 |
1997-07-22 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of nutriceuticals and compositions useful therefor
|
CN1245156C
(zh)
*
|
1993-02-22 |
2006-03-15 |
美国生物科学有限公司 |
用于体内传送生物制品的方法及用于该方法的组合物
|
US5997904A
(en)
*
|
1993-02-22 |
1999-12-07 |
American Bioscience, Inc. |
Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
|
US5916539A
(en)
*
|
1993-03-02 |
1999-06-29 |
Silica Gel Ges. M.B.H. |
Superparamagnetic particles, process for producing the same and their use
|
GB9312315D0
(en)
*
|
1993-06-15 |
1993-07-28 |
Poston Robin |
Leukocyte adhesion assay
|
EP0636363B1
(de)
*
|
1993-07-27 |
2001-05-23 |
Terumo Kabushiki Kaisha |
Verabreichungssystem für Arzneistoffe
|
AU694135B2
(en)
|
1993-07-30 |
1998-07-16 |
Imcor Pharmaceutical Company |
Stabilized microbubble compositions for ultrasound
|
US5798091A
(en)
|
1993-07-30 |
1998-08-25 |
Alliance Pharmaceutical Corp. |
Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
|
US5633003A
(en)
*
|
1994-03-31 |
1997-05-27 |
Cantor; Jerome O. |
Use of intratracheally administered hyaluronic acid to ameliorate emphysema
|
AUPM572294A0
(en)
*
|
1994-05-18 |
1994-06-09 |
Vaccine Technologies Pty. Ltd. |
Delivery vehicle for bioactive molecule
|
WO1996004922A1
(en)
*
|
1994-08-10 |
1996-02-22 |
Davis, Joanne, T. |
Method of using hyaluronic acid for the detection, location and diagnosis of tumors
|
FR2723849B1
(fr)
|
1994-08-31 |
1997-04-11 |
Biovector Therapeutics Sa |
Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
|
US5540909A
(en)
*
|
1994-09-28 |
1996-07-30 |
Alliance Pharmaceutical Corp. |
Harmonic ultrasound imaging with microbubbles
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5804162A
(en)
*
|
1995-06-07 |
1998-09-08 |
Alliance Pharmaceutical Corp. |
Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
|
AU6104896A
(en)
*
|
1995-06-07 |
1996-12-30 |
Regents Of The University Of California, The |
Therapeutic microdevices and methods of making and using sam e
|
US6107102A
(en)
*
|
1995-06-07 |
2000-08-22 |
Regents Of The University Of California |
Therapeutic microdevices and methods of making and using same
|
US6106866A
(en)
*
|
1995-07-31 |
2000-08-22 |
Access Pharmaceuticals, Inc. |
In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
|
AU1074897A
(en)
|
1995-11-08 |
1997-05-29 |
University Of South Florida |
Guinea pig model for leiomyomas and atherosclerosis
|
GB9600427D0
(en)
*
|
1996-01-10 |
1996-03-13 |
Nycomed Imaging As |
Contrast media
|
AU716667B2
(en)
|
1996-01-10 |
2000-03-02 |
Nycomed Imaging As |
Contrast media
|
US5855868A
(en)
*
|
1996-04-01 |
1999-01-05 |
Nycomed Imaging As |
Method of T1 -weighted resonance imaging of RES organs
|
ES2243994T5
(es)
|
1996-04-19 |
2009-10-29 |
Grifols Inc. |
Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
|
EP1369111A1
(de)
*
|
1996-10-03 |
2003-12-10 |
Hermes Biosciences, Inc. |
Hydrophile Mikropartikel und Verfahren zu deren Herstellung
|
US6096291A
(en)
*
|
1996-12-27 |
2000-08-01 |
Biovector Therapeutics, S.A. |
Mucosal administration of substances to mammals
|
JP4272811B2
(ja)
*
|
1997-09-05 |
2009-06-03 |
マルホ株式会社 |
関節内疾患治療用のナノカプセル製剤
|
US6489306B2
(en)
|
1998-02-23 |
2002-12-03 |
University Of South Florida |
Method of intranasal gene transfer for protection against respiratory infection
|
US6028102A
(en)
*
|
1998-02-24 |
2000-02-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anticonvulsant drugs and pharmaceutical compositions thereof
|
US6338834B1
(en)
|
1998-04-30 |
2002-01-15 |
The Curators Of The University Of Missouri |
Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
|
US20020086852A1
(en)
*
|
1998-05-14 |
2002-07-04 |
Cantor Jerome O. |
Method for treating respiratory disorders associated with pulmonary elastic fiber injury
|
US6391861B1
(en)
|
1998-05-14 |
2002-05-21 |
The Trustees Of Columbia University In The City Of New York |
Method for the prevention of tissue elastic fiber injury
|
US6344443B1
(en)
|
1998-07-08 |
2002-02-05 |
University Of South Florida |
Peptide antagonists of tumor necrosis factor alpha
|
AU4994899A
(en)
|
1998-07-13 |
2000-02-01 |
University Of South Florida |
Modulation of the phospholipase a2 pathway as a therapeutic
|
AU5329599A
(en)
*
|
1998-07-30 |
2000-02-21 |
University Of South Florida |
Method for the modulation of function of transcription factors
|
US6780397B2
(en)
|
1998-09-01 |
2004-08-24 |
Curators Of The University Of Missouri |
Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
|
US6299980B1
(en)
|
1998-09-29 |
2001-10-09 |
Medtronic Ave, Inc. |
One step lubricious coating
|
US6379691B1
(en)
|
1998-09-29 |
2002-04-30 |
Medtronic/Ave, Inc. |
Uses for medical devices having a lubricious, nitric oxide-releasing coating
|
US6409987B1
(en)
|
1999-04-07 |
2002-06-25 |
Intimax Corporation |
Targeted agents useful for diagnostic and therapeutic applications
|
US6638974B1
(en)
|
1999-04-09 |
2003-10-28 |
University Of South Florida |
Ascorbyl esters for the treatment of cancer
|
US6787318B1
(en)
|
1999-06-01 |
2004-09-07 |
Roskamp Research Institute, Llc |
Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
|
US7135498B1
(en)
|
1999-06-14 |
2006-11-14 |
Henry Ford Health System |
Nitric oxide donors for inducing neurogenesis
|
DE60040299D1
(de)
*
|
1999-06-14 |
2008-10-30 |
Ford Henry Health System |
Stickstoffmonoxid-donoren zum induzieren von neurogenese
|
US7655423B2
(en)
*
|
1999-06-14 |
2010-02-02 |
Henry Ford Health System |
Nitric oxide donors for inducing neurogenesis
|
US6998232B1
(en)
|
1999-09-27 |
2006-02-14 |
Quark Biotech, Inc. |
Methods of diagnosing bladder cancer
|
US6462066B2
(en)
|
1999-12-02 |
2002-10-08 |
University Of South Florida |
Method and composition for treatment of ischemic neuronal reperfusion injury
|
AU2002218744A1
(en)
*
|
2000-07-11 |
2002-01-21 |
University Of South Florida |
Bax fragment induced tumor cell death
|
US6803060B2
(en)
|
2000-09-07 |
2004-10-12 |
Joe Reyes |
Composition to boost libido
|
US20070154399A1
(en)
*
|
2000-10-27 |
2007-07-05 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
US20070031372A1
(en)
*
|
2004-08-05 |
2007-02-08 |
Hadden John W |
Vaccine immunotherapy for immune suppressed patients
|
US20060194242A1
(en)
*
|
2000-10-27 |
2006-08-31 |
Hadden John W |
Immunotherapy for immune suppressed patients
|
CA2950109C
(en)
*
|
2000-10-27 |
2019-02-19 |
John W. Hadden |
Vaccine immunotherapy for immune suppressed patients
|
US20070025958A1
(en)
*
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
US7182942B2
(en)
*
|
2000-10-27 |
2007-02-27 |
Irx Therapeutics, Inc. |
Vaccine immunotherapy for immune suppressed patients
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
US7172770B2
(en)
*
|
2001-02-19 |
2007-02-06 |
Board Of Regents, The University Of Texas System |
Mesoporous compositions for use in drug delivery
|
US6770622B2
(en)
|
2001-06-08 |
2004-08-03 |
Gary A. Jarvis |
N-terminally truncated galectin-3 for use in treating cancer
|
US7731945B2
(en)
*
|
2001-10-26 |
2010-06-08 |
Immuno-Rx, Inc. |
Immunotherapy for reversing immune suppression
|
EP1389487B1
(de)
*
|
2002-07-16 |
2006-05-03 |
Seiko Epson Corporation |
Mikrokapselhaltige Zusammensetzung für elektrophoretische Anzeigen
|
WO2004037204A2
(en)
*
|
2002-10-25 |
2004-05-06 |
University Of South Florida |
Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
|
WO2005021065A2
(en)
*
|
2003-08-29 |
2005-03-10 |
New York University |
Indirect delivery of growth factors into the central nervous system
|
US20050059610A1
(en)
*
|
2003-09-12 |
2005-03-17 |
Paul Wischmeyer |
Glutamine for use in treating injury
|
WO2005059100A2
(en)
*
|
2003-12-12 |
2005-06-30 |
New York University |
Methods and compositions relating to cystatin c
|
EP1758998B1
(de)
|
2004-01-30 |
2010-12-15 |
Quark Pharmaceuticals, Inc. |
Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
|
KR101094617B1
(ko)
|
2004-08-16 |
2011-12-15 |
사일런스 테라퓨틱스 아게 |
알티피801 억제제의 치료적 용도
|
DE112005002270T5
(de)
*
|
2004-09-28 |
2007-08-30 |
Osaka University |
Dreidimensionales Führungssystem und Verfahren, und Arznei-Zuführungssystem
|
AU2005288522B2
(en)
|
2004-09-28 |
2012-06-28 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
WO2007080129A1
(en)
|
2006-01-13 |
2007-07-19 |
A Chan Holding B.V. |
Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
US20080260678A1
(en)
*
|
2006-10-10 |
2008-10-23 |
University Of Colorado |
Molecular band-aid
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US8729121B2
(en)
|
2007-06-25 |
2014-05-20 |
Adhezion Biomedical, Llc |
Curing accelerator and method of making
|
DK2170403T3
(da)
|
2007-06-27 |
2014-06-16 |
Quark Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
|
WO2009044392A2
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
EP2742875B1
(de)
|
2007-11-14 |
2016-02-24 |
Adhezion Biomedical, LLC |
Cyanoacrylgewebehaftstoffe
|
US8486528B2
(en)
*
|
2008-01-22 |
2013-07-16 |
Gwangju Institute Of Science And Technology |
Temperature-sensitive nano-carriers
|
EP2106791A1
(de)
|
2008-03-31 |
2009-10-07 |
Biotempt B.V. |
Glutamin oder Glutamine enthaltendes Dipeptide in einer spezifischen Dosierung für die Behandlung von Entzündungen
|
US8198344B2
(en)
|
2008-06-20 |
2012-06-12 |
Adhezion Biomedical, Llc |
Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
|
US8293838B2
(en)
*
|
2008-06-20 |
2012-10-23 |
Adhezion Biomedical, Llc |
Stable and sterile tissue adhesive composition with a controlled high viscosity
|
US20110117047A1
(en)
|
2008-06-23 |
2011-05-19 |
Adhezion Biomedical, Llc |
Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
|
US8652510B2
(en)
|
2008-10-31 |
2014-02-18 |
Adhezion Biomedical, Llc |
Sterilized liquid compositions of cyanoacrylate monomer mixtures
|
US8609128B2
(en)
*
|
2008-10-31 |
2013-12-17 |
Adhezion Biomedical, Llc |
Cyanoacrylate-based liquid microbial sealant drape
|
US9254133B2
(en)
|
2008-10-31 |
2016-02-09 |
Adhezion Biomedical, Llc |
Sterilized liquid compositions of cyanoacrylate monomer mixtures
|
WO2010080452A2
(en)
|
2008-12-18 |
2010-07-15 |
Quark Pharmaceuticals, Inc. |
siRNA COMPOUNDS AND METHODS OF USE THEREOF
|
US9149509B2
(en)
|
2009-03-26 |
2015-10-06 |
Henry Ford Health System |
Methods for improving neurological outcome after neural injury and neurodegenerative disease
|
EP2440214A4
(de)
|
2009-06-08 |
2013-07-31 |
Quark Pharmaceuticals Inc |
Verfahren zur behandlung chronischer nierenkrankheiten
|
WO2011066475A1
(en)
|
2009-11-26 |
2011-06-03 |
Quark Pharmaceuticals, Inc. |
Sirna compounds comprising terminal substitutions
|
KR101692063B1
(ko)
|
2009-12-09 |
2017-01-03 |
닛토덴코 가부시키가이샤 |
hsp47 발현의 조절
|
EP2510098B1
(de)
|
2009-12-09 |
2015-02-11 |
Quark Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des zns
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
EP2538951B1
(de)
|
2010-02-22 |
2020-04-22 |
Health Enhancement Products Inc. |
Mittel und mechanismen zur vorbeugung von hypercholesterinämie
|
US9309019B2
(en)
|
2010-05-21 |
2016-04-12 |
Adhezion Biomedical, Llc |
Low dose gamma sterilization of liquid adhesives
|
KR101553753B1
(ko)
|
2010-06-24 |
2015-09-16 |
쿠아크 파마수티칼스 인코퍼레이티드 |
Rhoa에 대한 이중 가닥 rna 및 그의 용도
|
US20140134231A1
(en)
|
2010-10-11 |
2014-05-15 |
Sanford-Burnham Medical Research Institute |
Mir-211 expression and related pathways in human melanoma
|
CN103298939A
(zh)
|
2010-12-06 |
2013-09-11 |
夸克医药公司 |
包含位置修饰的双链寡核苷酸化合物
|
US9205100B2
(en)
|
2011-03-03 |
2015-12-08 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treating lung disease and injury
|
SG10201604479YA
(en)
|
2011-03-03 |
2016-07-28 |
Quark Pharmaceuticals Inc |
Oligonucleotide Modulators Of The Toll-Like Receptor Pathway
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
EP2776565A1
(de)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems
|
CN104080480A
(zh)
|
2012-01-01 |
2014-10-01 |
奇比艾企业有限公司 |
用于选择性递送治疗剂和诊断剂的endo180靶向微粒
|
WO2013106494A1
(en)
|
2012-01-12 |
2013-07-18 |
Quark Pharmaceuticals, Inc. |
Combination therapy for treating hearing and balance disorders
|
WO2013173923A1
(en)
|
2012-05-25 |
2013-11-28 |
Diamedica, Inc. |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
SI2854841T1
(sl)
|
2012-06-04 |
2017-06-30 |
Diamedica Inc. |
Glikozilacijske izooblike humanega tkivnega kalikreina-1
|
JP5918909B2
(ja)
|
2012-06-25 |
2016-05-18 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
標的化治療薬
|
WO2014043291A1
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded nucleic acid compounds
|
EP2895608B1
(de)
|
2012-09-12 |
2018-12-05 |
Quark Pharmaceuticals, Inc. |
Doppelsträngige oligonukleotidmoleküle an p53 und verfahren zur verwendung davon
|
CA2880290C
(en)
|
2012-09-12 |
2020-10-27 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof
|
BR112015015258A2
(pt)
|
2012-12-24 |
2017-09-26 |
Neurogastrx Inc |
métodos para tratar distúrbios do trato gastrintestinal
|
CA2904978A1
(en)
|
2013-03-12 |
2014-10-09 |
The General Hospital Corporation |
Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
|
US9539265B2
(en)
|
2013-03-15 |
2017-01-10 |
Aihol Corporation |
Pharmaceutical formulation containing glycosaminoglycan
|
WO2014142938A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Aihol Corporation |
Pharmaceutical formulation containing glycosaminoglycan
|
US10232028B2
(en)
|
2013-06-13 |
2019-03-19 |
Zivo Bioscience, Inc. |
Compounds and methods for affecting cytokines
|
WO2015020960A1
(en)
|
2013-08-09 |
2015-02-12 |
Novartis Ag |
Novel lncrna polynucleotides
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
US9421297B2
(en)
|
2014-04-02 |
2016-08-23 |
Adhezion Biomedical, Llc |
Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
|
WO2015200369A1
(en)
|
2014-06-24 |
2015-12-30 |
Neurogastrx, Inc. |
Prodrugs of metopimazine
|
EP3258948B1
(de)
|
2015-02-16 |
2023-12-06 |
Zivo Bioscience, Inc. |
Anti-entzündliche und immunomodulatorische zusammensetzungen, enthaltend klebsormidium und verwendungen davon
|
WO2017142906A1
(en)
|
2016-02-16 |
2017-08-24 |
Zivo Bioscience, Inc. |
Nutritional support for animals via administration of an algal derived supplement
|
JP2020510023A
(ja)
|
2017-03-09 |
2020-04-02 |
ダイアメディカ, インコーポレイテッド |
組織カリクレイン1の剤形
|
US10836757B1
(en)
|
2020-04-02 |
2020-11-17 |
Neurogastrx, Inc. |
Polymorphic forms of metopimazine
|
EP3922720A1
(de)
|
2020-06-09 |
2021-12-15 |
Universidad de Murcia |
Therapie zur verhinderung unerwünschter kardialer remodellierung nach einem akuten myokardinfarkt
|
US20220265582A1
(en)
|
2021-02-24 |
2022-08-25 |
Universitätsspital Basel |
Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
|
US11801256B2
(en)
|
2021-06-08 |
2023-10-31 |
Universitätsspital Basel |
Antidepressant-psilocybin co-treatment to assist psychotherapy
|